Harnessing Oxidative Stress to Kill Hepatocellular Carcinoma Cancer Cells: The Power of Methylselenic Acid and/or Pharmacological Ascorbate Combination—An In Vitro Study
Rattachement africain : jo. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background Hepatocellular carcinoma (HCC) is an aggressive and common liver cancer with high recurrence and late‐stage diagnosis. Despite multiple treatment options, their effectiveness is limited, especially in advanced stages. Hepatocellular cancer cells show elevated oxidative stress, which can be targeted therapeutically. Pharmacological ascorbate (P‐AscH − ) and methylseleninic acid (MSA) are redox‐active agents that are selectively cytotoxic to cancer cells by increasing reactive oxygen species (ROS) generation. However, the therapeutic potential of new redox‐active agents in HCC is still poorly investigated. Methods HepG2 and THLE‐3 cells were treated with increasing concentrations of P‐AscH − (0–20 mM), MSA (0–40 µM), or a combination of both. Cell viability was assessed using the MTS assay. ROS levels, particularly hydroxyl radicals, were measured using the OH580 fluorescent probe. Catalase (CAT) activity and concentration were quantified via a colorimetric assay and ELISA, respectively. Results P‐AscH − and MSA each induced dose‐dependent cytotoxicity in HepG2 cells without significantly affecting THLE‐3 normal liver cells. The combination treatment exhibited enhanced cytotoxicity in HepG2 cells, suggesting synergistic effects. ROS analysis revealed increased hydroxyl radical production in the combination group. Furthermore, CAT activity and expression were significantly altered in HepG2 cells treated with both agents, indicating impaired antioxidant defense and enhanced oxidative damage. Conclusion The combination of P‐AscH − and MSA selectively enhances cytotoxicity in HCC cells by increasing oxidative stress and suppressing CAT activity. These findings support further exploration of this combinatory approach as a potential therapeutic strategy for HCC.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Harnessing Oxidative Stress to Kill Hepatocellular Carcinoma Cancer Cells: The Power of Methylselenic Acid and/or Pharmacological Ascorbate Combination—An In Vitro Study
- Date Crossref
- 01/01/2026
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Yarmouk University pays non établi dans la noticeUniversité ou école supérieure
-
Hashemite University pays non établi dans la noticeUniversité ou école supérieure
-
Ministry of Health pays non établi dans la noticeOrganisme public
-
Faculty of Pharmacy Department of Clinical Pharmacy and Pharmacy Practice pays non établi dans la noticeUniversité ou école supérieure
-
Faculty of Pharmaceutical Sciences Department of Clinical Pharmacy and Pharmacy Practice pays non établi dans la noticeUniversité ou école supérieure
-
Department of Clinical Pharmacy pays non établi dans la noticeÉtablissement de santé
-
Faculty of Medicine Department of Basic Medical Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Ministry of Education Department of Biology pays non établi dans la noticeOrganisme public
Yarmouk University, Hashemite University et Ministry of Health, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.